查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1570724

晚期復发性卵巢癌市场：依疾病类型、治疗类型划分 - 全球预测 2025-2030

Advanced Recurrent Ovarian Cancer Market by Disease Type (Epithelial Ovarian Cancer, Non-Epithelial Ovarian Cancer), Treatment Type (Chemotherapy, Hormonal Therapy, Targeted Therapy) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年晚期復发性卵巢癌市值为14.3亿美元，预计2024年将达15.3亿美元，复合年增长率为9.15%，到2030年将达到26.4亿美元。

晚期復发性卵巢癌市场的范围和定义包括疾病进展和復发的研究，重点是治疗和诊断的进展。这个市场需要了解患者的需求、治疗效果和医疗保健提供者的要求。市场开拓研究的应用对于药物开发、设计有效的治疗方法、改进早期检测方法和加强患者照护至关重要。最终用途包括製药公司、生物技术公司、研究机构以及直接参与诊断和治疗的医疗保健提供者。影响成长的关键因素包括生物技术的进步、个人化医疗、卵巢癌盛行率的增加以及对有效治疗方案不断增长的需求。投资研发、生物技术公司之间的合作以及利用人工智慧进行药物发现都是主要的商机。特别是，正在进行的 PARP 抑制剂和免疫肿瘤治疗研究有可能带来突破。然而，高昂的治疗成本、严格的监管要求以及先进治疗意识有限等限制因素给市场拓展带来了挑战。此外，与抗治疗性和患者反应变异相关的问题需要持续创新。公司可以探索一些领域，例如开发针对基因图谱的标靶治疗以及增强伴同性诊断工具以改善治疗方法配对。改善现有药物的安全性和尽量减少副作用的研究也将推动成长。市场的本质是动态的，并受到技术进步和监管环境的影响，这要求公司保持敏捷。研究表明，将优先考虑与研究机构合作进行协作研究，投资资料分析以更好地预测结果，并专注于以患者为中心的方法来提高患者的参与度。总体而言，治疗方法和患者管理策略的创新对于该市场的业务成长仍然至关重要。

主要市场统计
基准年[2023] 14.3亿美元
预测年份 [2024] 15.3亿美元
预测年份 [2030] 26.4亿美元
复合年增长率（%） 9.15%

市场动态：揭示快速发展的晚期復发性卵巢癌市场的关键市场洞察

供需的动态交互作用正在改变晚期復发性卵巢癌市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，以及消费行为及其对製造成本的影响及其对采购趋势的影响。

波特五力：驾驭晚期復发性卵巢癌市场的策略工具

波特的五力框架是了解晚期復发性卵巢癌市场竞争格局的关键工具。波特的五力框架描述了评估公司竞争和探索策略机会的清晰方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解晚期復发性卵巢癌市场的外部影响

外部宏观环境因素在塑造晚期復发性卵巢癌市场的绩效动态发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助企业预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解晚期復发性卵巢癌市场的竞争格局

对晚期復发性卵巢癌市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、细分和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵高阶復发性卵巢癌市场供应商的绩效评估

FPNV定位矩阵是评估晚期復发性卵巢癌市场供应商的关键工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，为晚期復发性卵巢癌市场制定成功之路

对于旨在加强在全球市场的影响力的公司来说，晚期復发性卵巢癌市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

该报告提供了涵盖主要焦点细分市场的全面市场分析。

1. 市场渗透率：对当前市场环境的详细回顾。

2. 市场开拓：辨识新兴市场的成长机会，评估现有产业的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检视市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策。

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品和地区提供最佳投资机会？

3.塑造市场的关键技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 专门针对復发性卵巢癌的标靶治疗的开发和核准增加
      • 扩大临床试验计划，重点关注晚期和復发性卵巢癌的创新治疗方法
      • 透过製药公司和研究机构之间的合作推广新治疗方法
      • 增加对个人化医疗的投资有助于促进復发性卵巢癌的有效治疗策略
    • 抑制因素
      • 晚期復发性卵巢癌的早期诊断和缺乏特异性生物标记
      • 目前晚期復发性卵巢癌治疗通讯协定相关的副作用和毒性
    • 机会
      • 应用人工智慧和机器学习预测晚期復发性卵巢癌的治疗反应和结果
      • 为医疗保健专业人员开发晚期復发性卵巢的教育计划和资源
      • 晚期復发性卵巢癌将患者报告的结果和真实世界的证据整合到临床试验中，以实现更个人化的治疗
    • 任务
      • 确保为晚期和復发性卵巢癌研究提供充足的资金和资源
      • 解决晚期和復发性卵巢癌治疗的患者可近性和负担能力问题。
  • 市场区隔分析
  • 波特五力分析
  • PESTLE分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

第六章晚期復发性卵巢癌市场：依疾病类型

  • 介绍
  • 上皮性卵巢癌
    • 透明细胞
    • 子宫内膜样
    • 黏液
    • 浆液性的
  • 非上皮性卵巢癌
    • 生殖细胞肿瘤
    • 间质瘤

第七章晚期復发性卵巢癌市场：依治疗类型

  • 介绍
  • 化疗
    • 非铂类化疗
      • 多西紫杉醇
      • 紫杉醇
    • 含铂类药物化疗
      • Carboplatin
      • Cisplatin
  • 荷尔蒙疗法
    • 来曲唑
    • 他莫昔芬
  • 标靶治疗
    • 抗血管新生剂
      • Bevacizumab
    • PARP抑制剂
      • 尼拉帕尼
      • 奥拉帕尼
      • 卢卡帕尼

第八章北美和南美晚期復发性卵巢癌市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太晚期復发性卵巢癌市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章欧洲、中东和非洲的晚期復发性卵巢癌市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议
Product Code: MRR-1A1A064BFFBB

The Advanced Recurrent Ovarian Cancer Market was valued at USD 1.43 billion in 2023, expected to reach USD 1.53 billion in 2024, and is projected to grow at a CAGR of 9.15%, to USD 2.64 billion by 2030.

The scope and definition of the market for advanced recurrent ovarian cancer involve the study of the disease's progression and reoccurrence, focusing on therapeutic and diagnostic advancements. This market encompasses the necessity to understand patient needs, treatment efficacy, and healthcare provider requirements. Applications of market research here are crucial for drug development, crafting effective therapies, improving early detection methods, and enhancing patient care. End-use scope extends to pharmaceutical companies, biotechnology firms, research institutions, and healthcare providers who directly engage with diagnosis and treatment. Key influencing growth factors include advancements in biotechnology, personalized medicine, increasing prevalence of ovarian cancer, and rising demand for effective treatment options. Investment in R&D, collaborations between biotech firms, and leveraging AI for drug discovery represent significant opportunities. Particularly, ongoing research into PARP inhibitors and immune-oncology therapies presents potential breakthroughs. However, limitations such as high treatment costs, stringent regulatory requirements, and limited awareness about advanced therapies pose challenges to market expansion. Furthermore, issues related to treatment resistance and variability in patient response necessitate continuous innovation. Businesses can explore areas like the development of targeted therapies tailored to genetic profiles or the enhancement of companion diagnostic tools for improved treatment matching. Research into improving the safety profiles of existing drugs and minimizing side effects can also drive growth. The nature of the market is dynamic, influenced by technological advancements and regulatory landscapes, requiring firms to stay agile. Insights suggest prioritizing partnerships with research institutions for collaborative studies, investing in data analytics for better outcome predictions, and focusing on patient-centric approaches to drive engagement. Overall, innovation in treatment modalities and patient management strategies remains pivotal for business growth in this market.

KEY MARKET STATISTICS
Base Year [2023] USD 1.43 billion
Estimated Year [2024] USD 1.53 billion
Forecast Year [2030] USD 2.64 billion
CAGR (%) 9.15%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Advanced Recurrent Ovarian Cancer Market

The Advanced Recurrent Ovarian Cancer Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing development and approval of targeted therapies specifically for recurrent ovarian cancer
    • Expanding clinical trial programs focused on innovative treatments for advanced recurrent ovarian cancer
    • Collaborations between pharmaceutical companies and research institutions advancing novel treatment approaches
    • Increasing investment in personalized medicine boosting effective treatment strategies for recurrent ovarian cancer
  • Market Restraints
    • Lack of early diagnosis and specific biomarkers for advanced recurrent ovarian cancer
    • Adverse side effects and toxicity associated with current treatment protocols for advanced recurrent ovarian cancer
  • Market Opportunities
    • Application of artificial intelligence and machine learning in predicting treatment responses and outcomes for advanced recurrent ovarian cancer
    • Development of educational programs and resources for healthcare professionals specializing in advanced recurrent ovarian cancer
    • Integration of patient-reported outcomes and real-world evidence into clinical trials for more personalized therapy in advanced recurrent ovarian cancer
  • Market Challenges
    • Ensuring adequate funding and resources for advanced recurrent ovarian cancer research
    • Addressing patient accessibility and affordability of advanced recurrent ovarian cancer therapies.

Porter's Five Forces: A Strategic Tool for Navigating the Advanced Recurrent Ovarian Cancer Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Advanced Recurrent Ovarian Cancer Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Advanced Recurrent Ovarian Cancer Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Advanced Recurrent Ovarian Cancer Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Advanced Recurrent Ovarian Cancer Market

A detailed market share analysis in the Advanced Recurrent Ovarian Cancer Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Advanced Recurrent Ovarian Cancer Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Advanced Recurrent Ovarian Cancer Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Advanced Recurrent Ovarian Cancer Market

A strategic analysis of the Advanced Recurrent Ovarian Cancer Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Advanced Recurrent Ovarian Cancer Market, highlighting leading vendors and their innovative profiles. These include AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Clovis Oncology, Eli Lilly and Company, Exelixis, Genentech, GSK, ImmunoGen, Johnson & Johnson, Merck & Co., Novartis, Pfizer, Regeneron Pharmaceuticals, Roche, Sanofi, Seagen, Tesaro, and Vertex Pharmaceuticals.

Market Segmentation & Coverage

This research report categorizes the Advanced Recurrent Ovarian Cancer Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Disease Type, market is studied across Epithelial Ovarian Cancer and Non-Epithelial Ovarian Cancer. The Epithelial Ovarian Cancer is further studied across Clear Cell, Endometrioid, Mucinous, and Serous. The Non-Epithelial Ovarian Cancer is further studied across Germ Cell Tumors and Stromal Tumors.
  • Based on Treatment Type, market is studied across Chemotherapy, Hormonal Therapy, and Targeted Therapy. The Chemotherapy is further studied across Non-Platinum Chemotherapy and Platinum-Based Chemotherapy. The Non-Platinum Chemotherapy is further studied across Docetaxel and Paclitaxel. The Platinum-Based Chemotherapy is further studied across Carboplatin and Cisplatin. The Hormonal Therapy is further studied across Letrozole and Tamoxifen. The Targeted Therapy is further studied across Anti-Angiogenic Agents and PARP Inhibitors. The Anti-Angiogenic Agents is further studied across Bevacizumab. The PARP Inhibitors is further studied across Niraparib, Olaparib, and Rucaparib.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing development and approval of targeted therapies specifically for recurrent ovarian cancer
      • 5.1.1.2. Expanding clinical trial programs focused on innovative treatments for advanced recurrent ovarian cancer
      • 5.1.1.3. Collaborations between pharmaceutical companies and research institutions advancing novel treatment approaches
      • 5.1.1.4. Increasing investment in personalized medicine boosting effective treatment strategies for recurrent ovarian cancer
    • 5.1.2. Restraints
      • 5.1.2.1. Lack of early diagnosis and specific biomarkers for advanced recurrent ovarian cancer
      • 5.1.2.2. Adverse side effects and toxicity associated with current treatment protocols for advanced recurrent ovarian cancer
    • 5.1.3. Opportunities
      • 5.1.3.1. Application of artificial intelligence and machine learning in predicting treatment responses and outcomes for advanced recurrent ovarian cancer
      • 5.1.3.2. Development of educational programs and resources for healthcare professionals specializing in advanced recurrent ovarian cancer
      • 5.1.3.3. Integration of patient-reported outcomes and real-world evidence into clinical trials for more personalized therapy in advanced recurrent ovarian cancer
    • 5.1.4. Challenges
      • 5.1.4.1. Ensuring adequate funding and resources for advanced recurrent ovarian cancer research
      • 5.1.4.2. Addressing patient accessibility and affordability of advanced recurrent ovarian cancer therapies.
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Advanced Recurrent Ovarian Cancer Market, by Disease Type

  • 6.1. Introduction
  • 6.2. Epithelial Ovarian Cancer
    • 6.2.1. Clear Cell
    • 6.2.2. Endometrioid
    • 6.2.3. Mucinous
    • 6.2.4. Serous
  • 6.3. Non-Epithelial Ovarian Cancer
    • 6.3.1. Germ Cell Tumors
    • 6.3.2. Stromal Tumors

7. Advanced Recurrent Ovarian Cancer Market, by Treatment Type

  • 7.1. Introduction
  • 7.2. Chemotherapy
    • 7.2.1. Non-Platinum Chemotherapy
      • 7.2.1.1. Docetaxel
      • 7.2.1.2. Paclitaxel
    • 7.2.2. Platinum-Based Chemotherapy
      • 7.2.2.1. Carboplatin
      • 7.2.2.2. Cisplatin
  • 7.3. Hormonal Therapy
    • 7.3.1. Letrozole
    • 7.3.2. Tamoxifen
  • 7.4. Targeted Therapy
    • 7.4.1. Anti-Angiogenic Agents
      • 7.4.1.1. Bevacizumab
    • 7.4.2. PARP Inhibitors
      • 7.4.2.1. Niraparib
      • 7.4.2.2. Olaparib
      • 7.4.2.3. Rucaparib

8. Americas Advanced Recurrent Ovarian Cancer Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Advanced Recurrent Ovarian Cancer Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Advanced Recurrent Ovarian Cancer Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie
  • 2. Amgen
  • 3. AstraZeneca
  • 4. Bristol-Myers Squibb
  • 5. Clovis Oncology
  • 6. Eli Lilly and Company
  • 7. Exelixis
  • 8. Genentech
  • 9. GSK
  • 10. ImmunoGen
  • 11. Johnson & Johnson
  • 12. Merck & Co.
  • 13. Novartis
  • 14. Pfizer
  • 15. Regeneron Pharmaceuticals
  • 16. Roche
  • 17. Sanofi
  • 18. Seagen
  • 19. Tesaro
  • 20. Vertex Pharmaceuticals

LIST OF FIGURES

  • FIGURE 1. ADVANCED RECURRENT OVARIAN CANCER MARKET RESEARCH PROCESS
  • FIGURE 2. ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ADVANCED RECURRENT OVARIAN CANCER MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. ADVANCED RECURRENT OVARIAN CANCER MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ADVANCED RECURRENT OVARIAN CANCER MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ADVANCED RECURRENT OVARIAN CANCER MARKET DYNAMICS
  • TABLE 7. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY EPITHELIAL OVARIAN CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CLEAR CELL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ENDOMETRIOID, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY MUCINOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY SEROUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-EPITHELIAL OVARIAN CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY GERM CELL TUMORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY STROMAL TUMORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-PLATINUM CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY DOCETAXEL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PACLITAXEL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-PLATINUM CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PLATINUM-BASED CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CARBOPLATIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CISPLATIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PLATINUM-BASED CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY LETROZOLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TAMOXIFEN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ANTI-ANGIOGENIC AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ANTI-ANGIOGENIC AGENTS, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PARP INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NIRAPARIB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY OLAPARIB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY RUCAPARIB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-PLATINUM CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 49. AMERICAS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PLATINUM-BASED CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 50. AMERICAS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 52. AMERICAS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ANTI-ANGIOGENIC AGENTS, 2018-2030 (USD MILLION)
  • TABLE 53. AMERICAS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 54. AMERICAS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 57. ARGENTINA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 58. ARGENTINA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. ARGENTINA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 60. ARGENTINA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-PLATINUM CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 61. ARGENTINA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PLATINUM-BASED CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 62. ARGENTINA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 63. ARGENTINA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 64. ARGENTINA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ANTI-ANGIOGENIC AGENTS, 2018-2030 (USD MILLION)
  • TABLE 65. ARGENTINA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 66. BRAZIL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. BRAZIL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 68. BRAZIL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 69. BRAZIL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. BRAZIL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 71. BRAZIL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-PLATINUM CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 72. BRAZIL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PLATINUM-BASED CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 73. BRAZIL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 74. BRAZIL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 75. BRAZIL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ANTI-ANGIOGENIC AGENTS, 2018-2030 (USD MILLION)
  • TABLE 76. BRAZIL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 77. CANADA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. CANADA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 79. CANADA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 80. CANADA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. CANADA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 82. CANADA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-PLATINUM CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 83. CANADA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PLATINUM-BASED CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 84. CANADA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 85. CANADA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 86. CANADA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ANTI-ANGIOGENIC AGENTS, 2018-2030 (USD MILLION)
  • TABLE 87. CANADA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 88. MEXICO ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. MEXICO ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 90. MEXICO ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 91. MEXICO ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. MEXICO ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 93. MEXICO ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-PLATINUM CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 94. MEXICO ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PLATINUM-BASED CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 95. MEXICO ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 96. MEXICO ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 97. MEXICO ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ANTI-ANGIOGENIC AGENTS, 2018-2030 (USD MILLION)
  • TABLE 98. MEXICO ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED STATES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED STATES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED STATES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 102. UNITED STATES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. UNITED STATES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 104. UNITED STATES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-PLATINUM CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 105. UNITED STATES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PLATINUM-BASED CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 106. UNITED STATES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 107. UNITED STATES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 108. UNITED STATES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ANTI-ANGIOGENIC AGENTS, 2018-2030 (USD MILLION)
  • TABLE 109. UNITED STATES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 110. UNITED STATES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-PLATINUM CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PLATINUM-BASED CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ANTI-ANGIOGENIC AGENTS, 2018-2030 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 123. AUSTRALIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. AUSTRALIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 125. AUSTRALIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 126. AUSTRALIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. AUSTRALIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 128. AUSTRALIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-PLATINUM CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 129. AUSTRALIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PLATINUM-BASED CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 130. AUSTRALIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 131. AUSTRALIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 132. AUSTRALIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ANTI-ANGIOGENIC AGENTS, 2018-2030 (USD MILLION)
  • TABLE 133. AUSTRALIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 134. CHINA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. CHINA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 136. CHINA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 137. CHINA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. CHINA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 139. CHINA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-PLATINUM CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 140. CHINA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PLATINUM-BASED CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 141. CHINA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 142. CHINA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 143. CHINA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ANTI-ANGIOGENIC AGENTS, 2018-2030 (USD MILLION)
  • TABLE 144. CHINA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 145. INDIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. INDIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 147. INDIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 148. INDIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. INDIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 150. INDIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-PLATINUM CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 151. INDIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PLATINUM-BASED CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 152. INDIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 153. INDIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 154. INDIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ANTI-ANGIOGENIC AGENTS, 2018-2030 (USD MILLION)
  • TABLE 155. INDIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 156. INDONESIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. INDONESIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 158. INDONESIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 159. INDONESIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. INDONESIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 161. INDONESIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-PLATINUM CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 162. INDONESIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PLATINUM-BASED CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 163. INDONESIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 164. INDONESIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 165. INDONESIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ANTI-ANGIOGENIC AGENTS, 2018-2030 (USD MILLION)
  • TABLE 166. INDONESIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 167. JAPAN ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. JAPAN ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 169. JAPAN ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 170. JAPAN ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. JAPAN ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 172. JAPAN ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-PLATINUM CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 173. JAPAN ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PLATINUM-BASED CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 174. JAPAN ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 175. JAPAN ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 176. JAPAN ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ANTI-ANGIOGENIC AGENTS, 2018-2030 (USD MILLION)
  • TABLE 177. JAPAN ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 178. MALAYSIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. MALAYSIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 180. MALAYSIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 181. MALAYSIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. MALAYSIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 183. MALAYSIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-PLATINUM CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 184. MALAYSIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PLATINUM-BASED CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 185. MALAYSIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 186. MALAYSIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 187. MALAYSIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ANTI-ANGIOGENIC AGENTS, 2018-2030 (USD MILLION)
  • TABLE 188. MALAYSIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 189. PHILIPPINES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. PHILIPPINES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 191. PHILIPPINES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 192. PHILIPPINES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. PHILIPPINES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 194. PHILIPPINES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-PLATINUM CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 195. PHILIPPINES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PLATINUM-BASED CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 196. PHILIPPINES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 197. PHILIPPINES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 198. PHILIPPINES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ANTI-ANGIOGENIC AGENTS, 2018-2030 (USD MILLION)
  • TABLE 199. PHILIPPINES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 200. SINGAPORE ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. SINGAPORE ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 202. SINGAPORE ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 203. SINGAPORE ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 204. SINGAPORE ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 205. SINGAPORE ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-PLATINUM CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 206. SINGAPORE ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PLATINUM-BASED CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 207. SINGAPORE ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 208. SINGAPORE ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 209. SINGAPORE ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ANTI-ANGIOGENIC AGENTS, 2018-2030 (USD MILLION)
  • TABLE 210. SINGAPORE ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 211. SOUTH KOREA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 212. SOUTH KOREA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 213. SOUTH KOREA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 214. SOUTH KOREA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 215. SOUTH KOREA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 216. SOUTH KOREA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-PLATINUM CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 217. SOUTH KOREA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PLATINUM-BASED CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 218. SOUTH KOREA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 219. SOUTH KOREA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 220. SOUTH KOREA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ANTI-ANGIOGENIC AGENTS, 2018-2030 (USD MILLION)
  • TABLE 221. SOUTH KOREA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 222. TAIWAN ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 223. TAIWAN ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 224. TAIWAN ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 225. TAIWAN ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. TAIWAN ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 227. TAIWAN ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-PLATINUM CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 228. TAIWAN ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PLATINUM-BASED CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 229. TAIWAN ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 230. TAIWAN ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 231. TAIWAN ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ANTI-ANGIOGENIC AGENTS, 2018-2030 (USD MILLION)
  • TABLE 232. TAIWAN ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 233. THAILAND ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 234. THAILAND ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 235. THAILAND ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 236. THAILAND ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 237. THAILAND ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 238. THAILAND ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-PLATINUM CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 239. THAILAND ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PLATINUM-BASED CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 240. THAILAND ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 241. THAILAND ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 242. THAILAND ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ANTI-ANGIOGENIC AGENTS, 2018-2030 (USD MILLION)
  • TABLE 243. THAILAND ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 244. VIETNAM ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 245. VIETNAM ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 246. VIETNAM ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 247. VIETNAM ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 248. VIETNAM ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 249. VIETNAM ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-PLATINUM CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 250. VIETNAM ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PLATINUM-BASED CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 251. VIETNAM ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 252. VIETNAM ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 253. VIETNAM ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ANTI-ANGIOGENIC AGENTS, 2018-2030 (USD MILLION)
  • TABLE 254. VIETNAM ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-PLATINUM CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PLATINUM-BASED CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ANTI-ANGIOGENIC AGENTS, 2018-2030 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 267. DENMARK ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 268. DENMARK ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 269. DENMARK ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 270. DENMARK ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 271. DENMARK ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 272. DENMARK ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-PLATINUM CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 273. DENMARK ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PLATINUM-BASED CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 274. DENMARK ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 275. DENMARK ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 276. DENMARK ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ANTI-ANGIOGENIC AGENTS, 2018-2030 (USD MILLION)
  • TABLE 277. DENMARK ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 278. EGYPT ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 279. EGYPT ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 280. EGYPT ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 281. EGYPT ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 282. EGYPT ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 283. EGYPT ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-PLATINUM CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 284. EGYPT ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PLATINUM-BASED CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 285. EGYPT ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY